tweetindex
ID

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 ✓

@Rfonsi1 · joined 22 May 2010

Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement

15 873Followers
2 605Following
20 752Posts total
34.1KViews on collected posts

Postingan terbaru

Rest in peace Dr. Kyle. Founder of the myeloma team. Mentor to many. Advocate for patients. Supporter and friend. Bob Kyle - a man of determined significance 4.3K views · 64 likes · 17 reposts · 2 replies Open on X →
RVD followed by SCT. Brief maintenance with rev, stopped in all treatment in 4/2022. Close to another cure? https://t.co/sLYINSjRlD
2.2K views · 14 likes · 2 reposts · 1 replies Open on X →
@Rfonsi1 Great Rafael! Can you write it up for us. 395 views · 3 likes · 1 reposts · 0 replies Open on X →
Thanks Rahul! An important point, and I will add it to the write-up. The time from collection to infusion can be flexible. Also useful if other medical problems arise. 2.4K views · 14 likes · 3 reposts · 0 replies Open on X →
Eloquently written as always! 100% agree with @Rfonsi1’s description of evolving peri-CAR-T world in myeloma. With cilta-cel we have ≤ 9 months to use the product. Generally worth the wait if LD delayed by few weeks to knock MM down with diff bridging (e.g., tal or CELMoD). ht
9.7K views · 53 likes · 10 reposts · 4 replies Open on X →
@Rfonsi1 Very nice write up ! Our ability to target MM has revolved significantly in recent years; now we need to put same efforts in understanding the pathobiology of the AE’s 297 views · 3 likes · 0 reposts · 0 replies Open on X →
@Rfonsi1 This is very well written and largely reflects my practice as well. I think the toughest cases are those with many prior therapies and who have middling responses to bridging therapy. It’s often a case of extending the time to infusion with the risk of losing the window 1.2K views · 9 likes · 2 reposts · 1 replies Open on X →
How I treat relapsing myeloma (MM) with CART (cilta-cel). https://t.co/owyM8bWGNB #mmsm https://t.co/VRffA8IGr8
13.5K views · 65 likes · 24 reposts · 5 replies Open on X →
What is human existence, but our daily quest to defend our domain from entropy? 0 views · 175 likes · 14 reposts · 29 replies Open on X →

Dibandingkan akun berukuran sama

8 postingan dari 90 hari terakhir, dibandingkan dengan rentang 10K–100K pengikut. tampil luas, tetapi sedikit penonton yang merespons.

Median tayangan2 330akun ini924median untuk 10K–100K
Jangkauan, %14.68%akun ini3.62%median untuk 10K–100K
Interaksi, %0.91%akun ini1.52%median untuk 10K–100K
MetrikAkun iniMedian untuk 10K–100KRasio
Median tayangan per postingan2 3309242.52×
Jangkauan (tayangan ÷ pengikut)14.68%3.62%4.05×
Tingkat interaksi0.91%1.52%0.60×

Akun lain pada rentang ini →   Bandingkan dengan akun lain →   Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

13.5K29 Aug
1.2K
297
9.7K30 Aug
2.4K
395
2.2K3 Sep
4.3K5 Sep

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.73%29 Aug
1.03%
1.01%
0.71%30 Aug
0.70%
1.01%
0.81%3 Sep
1.95%5 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes64.5%225 in total
Reposts16.9%59 in total
Replies3.7%13 in total
Quotes2.3%8 in total
Bookmarks12.6%44 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Akun serupa